FLASCO

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver



On February 15th FLASCO hosted a free “Living with Metastatic Breast Cancer” luncheon Patient Advocacy Program at the Capitol Building in Tallahassee. This educational program was for people who have this advanced type of cancer and their caregivers. The event featured speakers representing the Mayo Clinic Florida, Florida Cancer Specialists, Tallahassee Memorial Cancer Center, and the Florida Breast Cancer Foundation. The speakers discussed the disease itself, treatment options, patient advocacy, caring for the caregiver, and patient assistance programs. A question-and-answer session followed the formal presentations.

Celeste Phillip, MD, MPH, Florida Surgeon General and Secretary Florida Department of Health, joined us on behalf of Governor Scott, to present the Governor’s Proclamation declaring February 2017 as Metastatic Breast Cancer Awareness Month. Click here to read the Proclamation. We were pleased to also have Representative Lori Berman join the audience.

This event would not have been possible without the generous support of our sponsors and exhibitors. Thank you to our grant providers:Pfizer and Florida Breast Cancer Foundation, Meeting sponsor: NanoString Technologies, and Exhibitors: AstraZeneca and Insys.


Latest News

bayer health

FDA Approves Regorafenib for Liver Cancer

Posted April 27, 2017

On April 27, 2017 the U.S. Food and Drug Administration expanded the indications of regorafenib (STIVARGA, Bayer HealthCare Pharmaceuticals Inc.) to include the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Approval was based on an international, multicenter, randomized, double-blind, placebo-controlled trial of 573 patients with Child-Pugh A and...

FDA Approves Cancer Immunotherapy TECENTRIQ as Initial Treatment for Certain People with Advanced Bladder Cancer

Posted April 18, 2017

The FDA approved Tecentriq (atezolizumab) as a first-line treatment for people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. The Genentech press release including Important Safety Information is linked here. This approval is important news for a number of reasons: According to the American Cancer Society, it is...

FDA removes Risk Evaluation Management Strategies (REMS) for ESAs

Posted April 13, 2017

U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy. Below is the Agency’s announcement regarding this action: Epoetin alfa and darbepoetin alfa are Erythropoiesis-Stimulating Agents (ESAs), approved for the treatment of anemia (low...

FLASCO Spring Meeting Highlights

Posted April 6, 2017

Business of Oncology Spring Session Administrator Track Gallery On March 31st FLASCO Hosted the 2017 Business of Oncology. This year’s theme was Disruption as the Driver for Innovation and Change. Attendees gained cutting-edge perspectives on how DISRUPTIONS in healthcare policy will affect their oncology practice and the care of patients. The speakers and moderators examined...

Evaluate First Coast Service Options’ Services in 10 Minutes

Posted April 6, 2017

FCSO is requesting to hear from you!  Every year the Centers for Medicare & Medicaid Services (CMS) conducts the MAC Satisfaction Indicator survey to measure provider satisfaction with their MACs regarding the services FCSO perform for you. This survey is the best way for Medicare providers to share opinions directly with CMS about their experience...

Who’s Online

There are no users currently online